aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.46) per share which met the analyst consensus estimate. This is a 9.52 percent decrease over losses of $(0.42) per share from the same period last year.
Cel-Sci Corp Says Phase 3 Trial Showed Multikine Immunotherapy Extended Lives Of Patients With Locally Advanced Primary SCCHN
CEL-SCI Corporation (NYSE:CVM) today issued a letter to its shareholders.
Dear CEL-SCI Shareholders:
I wanted to write to update you on our progress. Our story is following the well-worn path of all
